Meta Biomed Balance Sheet Health
Financial Health criteria checks 6/6
Meta Biomed has a total shareholder equity of ₩86.0B and total debt of ₩56.9B, which brings its debt-to-equity ratio to 66.2%. Its total assets and total liabilities are ₩170.1B and ₩84.2B respectively. Meta Biomed's EBIT is ₩12.0B making its interest coverage ratio 4.2. It has cash and short-term investments of ₩48.8B.
Key information
66.2%
Debt to equity ratio
₩56.88b
Debt
| Interest coverage ratio | 4.2x |
| Cash | ₩48.80b |
| Equity | ₩85.97b |
| Total liabilities | ₩84.17b |
| Total assets | ₩170.14b |
Recent financial health updates
Recent updates
Meta Biomed (KOSDAQ:059210) Shareholders Will Want The ROCE Trajectory To Continue
Dec 17
Earnings Tell The Story For Meta Biomed Co., Ltd. (KOSDAQ:059210) As Its Stock Soars 30%
Feb 26Here's How We Evaluate Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Dividend
Apr 11Meta Biomed's (KOSDAQ:059210) Stock Price Has Reduced 58% In The Past Five Years
Mar 14Are Meta Biomed's (KOSDAQ:059210) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Can Meta Biomed (KOSDAQ:059210) Continue To Grow Its Returns On Capital?
Feb 03
Is Meta Biomed (KOSDAQ:059210) A Risky Investment?
Jan 13Here's Why I Think Meta Biomed (KOSDAQ:059210) Is An Interesting Stock
Dec 26Meta Biomed (KOSDAQ:059210) Share Prices Have Dropped 22% In The Last Five Years
Dec 08Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Nov 20Financial Position Analysis
Short Term Liabilities: A059210's short term assets (₩85.4B) exceed its short term liabilities (₩72.6B).
Long Term Liabilities: A059210's short term assets (₩85.4B) exceed its long term liabilities (₩11.6B).
Debt to Equity History and Analysis
Debt Level: A059210's net debt to equity ratio (9.4%) is considered satisfactory.
Reducing Debt: A059210's debt to equity ratio has reduced from 71.5% to 66.2% over the past 5 years.
Debt Coverage: A059210's debt is well covered by operating cash flow (31.5%).
Interest Coverage: A059210's interest payments on its debt are well covered by EBIT (4.2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 16:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Meta Biomed Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|